MDLN

Medline Inc. Class A Common Stock
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$72.18B
P/E Ratio
34.62
EPS
$1.17
Beta
52W High
$50.88
52W Low
$32.81
50-Day MA
$37.80
200-Day MA
$41.96
Dividend Yield
Profit Margin
3.32%
Forward P/E
26.95
PEG Ratio

About Medline Inc. Class A Common Stock

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$29.14B
Gross Profit (TTM)$7.54B
EBITDA$3.04B
Operating Margin5.43%
Return on Equity6.05%
Return on Assets3.66%
Revenue/Share (TTM)$34.44
Book Value$13.32
Price-to-Book2.98
Price-to-Sales (TTM)2.48
EV/Revenue1.509
EV/EBITDA14.90
Quarterly Earnings Growth (YoY)1258.00%
Quarterly Revenue Growth (YoY)10.70%
Shares Outstanding$845.61M
Float$356.90M
% Insiders0.21%
% Institutions101.47%

Historical Volatility

HV 10-Day
47.44%
HV 20-Day
51.09%
HV 30-Day
47.15%
HV 60-Day
50.47%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($50.92 target)
7
Strong Buy
17
Buy
4
Hold

Latest News

Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company

New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Newsfile Corp7/29/2026Neutral
Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Newsfile Corp7/24/2026Neutral
Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm

New York, New York--(Newsfile Corp. - July 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Newsfile Corp7/20/2026Neutral
MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigations

SAN FRANCISCO, July 7, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. (NASDAQ: MDLN) focusing on whether the company may have misled investors regarding the adequacy of its manufacturing quality controls and compliance with FDA safety standards. SUBMIT YOUR MDLN INVESTMENT LOSSES TO HBSS NOW The firm is looking into whether Medline concealed systemic lapses in its contamination protocols—specifically failures to investigate microbial incidents and batch discrepancies—that prompted regulatory scrutiny and triggered a significant decline in the company's share price.

PRNewsWire7/8/2026Neutral
MDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigations

SAN FRANCISCO, July 01, 2026 (GLOBE NEWSWIRE) -- National shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. (NASDAQ: MDLN) focusing on whether the company may have misled investors regarding the adequacy of its manufacturing quality controls and compliance with FDA safety standards. SUBMIT YOUR MDLN INVESTMENT LOSSES TO HBSS NOW The firm is looking into whether Medline concealed systemic lapses in its contamination protocols—specifically failures to investigate microbial incidents and batch discrepancies—that prompted regulatory scrutiny and triggered a significant decline in the company's share price.

GlobeNewsWire7/1/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDLN and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026